Ophthalmology Management – December 1
At AAO 2017, Sean Ianchulev, MD, MPH, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and director of the ophthalmic innovation and technology program at New York Eye and Ear Infirmary of Mount Sinai, questioned why the medical field is still using eyedropper technology that has not changed in 100 years. He presented data on the use of a new “microdosing” eyedropper technology that could end the complications associated with eyedrop overdosing. He shared results of the “piezo-ejection” microdose delivery system from a paper published in Therapeutic Delivery. To validate the ocular microtherapeutic approach, Dr. Ianchulev’s research team used the mydriatic response to pharmacologic dilation measured by digital pupillometry as it provides one of the most sensitive, quantifiable and immediate pharmacodynamic markers of biologic effect. Dr. Ianchulev said he expects phase 3 clinical trials in glaucoma, dry eye, myopia and pharmacologic dilation to begin in the next year, with the first microtherapeutic programs delivering phase 3 results in 2019 for mydriasis, followed by dry eye, glaucoma and myopia.
- Sean Ianchulev, MD, MPH, Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai, Director of the Ophthalmic Innovation and Technology Program, New York Eye and Ear Infirmary of Mount Sinai